Welcome to our dedicated page for Exelixis SEC filings (Ticker: EXEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cabozantinib isn’t the only complex subject inside Exelixis’ SEC filings—royalty waterfalls, phase 3 milestones, and collaboration payments are buried in hundreds of pages. If you have ever wondered, “How do I find Exelixis’ latest 10-Q?” or searched for “Exelixis insider trading Form 4 transactions,” you know the challenge.
Stock Titan’s AI solves that problem. Our engine turns dense disclosures into plain-English takeaways, flagging where cabozantinib sales move the needle, which trials hit enrollment targets, and when executives file Form 4s. Whether you need an Exelixis quarterly earnings report 10-Q filing or an Exelixis annual report 10-K simplified, you’ll get real-time alerts and side-by-side metric trends—no manual page-skimming required.
All core documents are here and updated the moment EDGAR posts: 8-K material events explained, proxy statement executive compensation details, and Exelixis Form 4 insider transactions real-time. Use our AI-powered summaries to answer natural questions like “What did management earn this year?” or “Which trials could move revenue next quarter?” and compare segments without accounting jargon.
From Exelixis earnings report filing analysis to monitoring Exelixis executive stock transactions Form 4, professionals rely on Stock Titan to understand risk factors, royalty obligations, and pipeline timelines faster. Stop digging through PDFs—start understanding Exelixis SEC documents with AI today.
Exelixis (EXEL) posted mixed Q2 2025 results. Net product revenue rose 19% YoY to $520.0 m on continued CABOMETYX growth, lifting six-month product sales 27% to $1.03 b. However, the absence of last year’s $150 m Ipsen milestone drove collaboration revenue down 76% to $48.3 m, pulling total quarterly revenue to $568.3 m (-11%). Operating expenses were flat; yet operating income fell 23% to $213.6 m and net income slid 18% to $184.8 m, or $0.65 diluted EPS (vs $0.77).
Year-to-date momentum remains solid. For the first six months, revenue climbed 6% to $1.12 b and net income jumped 31% to $344.5 m ($1.20 EPS) thanks to stronger U.S. product demand and lower restructuring charges. Operating cash flow improved 38% to $260.4 m.
Capital allocation and balance sheet. The company repurchased 21.7 m shares for $796 m, trimming cash and investments to $1.38 b (-21% YTD) and reducing shares outstanding to 270.1 m. Equity compensation expense was $62 m (+39%).
Pipeline & legal. EXEL settled with Biocon, deferring U.S. generic entry until 1 Jan 2031. ANDA challenges from MSN, Sun and Azurity continue; recent Delaware rulings upheld key patents through 2030, but appeals are pending. R&D spend fell 5% to $200.4 m as the phase 3 zanzalintinib program advances.
Key metrics Q2 2025 vs Q2 2024:
- Total revenue $568.3 m vs $637.2 m
- Product gross margin ~96%
- GAAP EPS $0.65 vs $0.77
- Cash & investments $1.39 b
FAQ
What is the current stock price of Exelixis (EXEL)?
What is the market cap of Exelixis (EXEL)?
What is the core focus of Exelixis Inc?
Which cancer types does Exelixis primarily target?
How does Exelixis generate its revenue?
What role do strategic collaborations play in Exelixis' business model?
Can you describe the company’s approach to clinical development?
How does Exelixis maintain its market relevance in the oncology space?
What differentiates Exelixis from other companies in the oncology sector?
